Keratinocyte growth factor (KGF; palifermin or repifermin), intravenous vs placebo: Oral mucositis (any severity)
- Population
- Adults with cancer receiving treatment
- Intervention
- Keratinocyte growth factor (KGF; palifermin or repifermin), intravenous
- Comparison
- placebo
- Outcome
- Oral mucositis (any severity)
Keratinocyte growth factor (KGF; palifermin or repifermin),… showed no clear difference in oral mucositis (any severity) compared with placebo; GRADE not reported.
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Keratinocyte growth factor (KGF; palifermin or repifermin), intravenous vs Placebo Oral mucositis (any severity) · Adults with cancer receiving treatment · BMT/SCT after conditioning for haematological cancers Keratinocyte growth factor (KGF; palifermin or repifermin),… showed no clear difference in oral mucositis (any severity) compared with placebo; GRADE not reported. Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and… (2017) · Cochrane All outcomes | RR 0.96 [0.88, 1.05] | 4 studies · 655 participants | GRADE not reported |
Keratinocyte growth factor (KGF; palifermin or repifermin), intravenous vs Placebo Oral mucositis (any severity) · Adults with cancer receiving treatment · Children Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and… (2017) · Cochrane All outcomes | Two studies of KGF versus placebo in children were unclear in reporting; no usable data could be presented | 2 studies | GRADE not reported |
Keratinocyte growth factor (KGF; palifermin or repifermin), intravenous vs Placebo Oral mucositis (any severity) · Adults with cancer receiving treatment · RT to head and neck with cisplatin/fluorouracil Keratinocyte growth factor (KGF; palifermin or repifermin),… showed no clear difference in oral mucositis (any severity) compared with placebo; GRADE not reported. Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and… (2017) · Cochrane All outcomes | RR 0.95 [0.90, 1.00] | 2 studies · 374 participants | GRADE not reported |
Keratinocyte growth factor (KGF; palifermin or repifermin), intravenous vs Placebo Oral mucositis (any severity) · Adults with cancer receiving treatment · Chemotherapy alone for mixed cancers Keratinocyte growth factor (KGF; palifermin or repifermin),… led to lower oral mucositis (any severity) compared with placebo; GRADE not reported. Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and… (2017) · Cochrane All outcomes | RR 0.71 [0.60, 0.85] | 2 studies · 215 participants | GRADE not reported |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes | 2017-05 | Not listed | Not assessed |
Related questions
The same intervention and outcome, asked in another population or against another comparator.
- Keratinocyte growth factor (KGF; palifermin or repifermin), intravenous vs Chlorhexidine mouthwash · Children with acute lymphoblastic leukaemia receiving chemotherapy alone · 1 review
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.